Suzanne Louise Bruhn
Known title: DirectorCIK: 0001517790
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Transaction History
| DFTX | ▲ Buy | Grant | 4,666 | $0 | 6/11/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/15/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/8/2024 | View on chart |
| DFTX | ▲ Buy | Grant | 13,671 | $0 | 6/21/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 4,500 | $0 | 5/17/2023 | View on chart |
| DFTX | ▲ Buy | Grant | 89,286 | $0 | 8/11/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 3,000 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
JP Morgan Launches Coverage of DFTX with Overweight Rating
JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.
JP Morgan Launches Coverage of DFTX with Overweight Rating. JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.